ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

LL-37

LL-37

Also known as: Cathelicidin, hCAP-18 Fragment, CAMP

Overview

Key Facts

Primary Goal: Research and therapeutic applications of LL-37

Directly disrupts microbial cell membranes via amphipathic alpha-helix insertion. Inhibits bacterial biofilm matrix formation and promotes dispersal.

Dosing Information

Half-Life

~4 hours

Typical Dose

50–100 mcg

Frequency

1x daily or every other day

Cycle Length

4-8 weeks

Administration Routes:
subcutaneoustopical

Benefits

  • Broad-spectrum antimicrobial activity (bacteria, fungi, viruses)
  • Disrupts bacterial biofilm formation
  • Promotes wound healing and angiogenesis
  • Neutralizes bacterial endotoxin (LPS)
  • Recruits immune cells to infection sites (chemotactic)
  • Modulates adaptive immune response activation

Side Effects

Injection site irritation or stingingmild
Localized redness and swellingmild
Mild headache (uncommon)mild
Transient skin irritation with topical usemild

Mechanism of Action

1

Directly disrupts microbial cell membranes via amphipathic alpha-helix insertion

2

Inhibits bacterial biofilm matrix formation and promotes dispersal

3

Activates formyl peptide receptor-like 1 (FPRL1) for immune cell chemotaxis

4

Stimulates TLR-mediated immune signaling in macrophages and dendritic cells

5

Promotes keratinocyte migration and re-epithelialization in wounds

Contraindications

Do not use this peptide if any of the following apply:

  • Active rosacea or psoriasis (LL-37 overexpression implicated)
  • Pregnancy or breastfeeding
  • Known hypersensitivity to cathelicidin peptides
  • Active autoimmune skin conditions

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration1-2 weeks

Research Summary

Preclinical

Extensively studied innate immune peptide with over 2,000 published papers. Phase 1 clinical trials conducted for chronic wound healing (OP-145, a derivative). Strong preclinical data for biofilm-associated infections, diabetic wound healing, and adjunct antibiotic therapy. Vitamin D-dependent expression explains some immune benefits of vitamin D supplementation.

Frequently Asked Questions

Common questions about LL-37

UK-Specific Information

Exclusive data points and guidance for UK residents using LL-37

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok